Finance

Lists
500124:BOM
Dr Reddy's Laboratories Ltd
₹1 231,85
+0,91%
(+11,10) 1D
16 Okt., 15:59:49 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for 500124...
Open
₹1 227,10
High
₹1 231,85
Low
₹1 213,80
Mkt. cap
1,02 bn
Avg. vol.
87,44 k
Volume
77,54 k
Dividend
0,65%
Quarterly dividend
₹2,00
Ex-dividend date
10 Jul. 2026
P/E ratio
31,85
52-wk high
₹1 414,40
52-wk low
₹1 080,05
EPS
₹38,67
Shares outstanding
166,06 m
No. of employees
28 k
Open
₹1 227,10
High
₹1 231,85
Low
₹1 213,80
Mkt. cap
1,02 bn
Avg. vol.
87,44 k
Volume
77,54 k
Dividend
0,65%
Quarterly dividend
₹2,00
Ex-dividend date
10 Jul. 2026
P/E ratio
31,85
52-wk high
₹1 414,40
52-wk low
₹1 080,05
EPS
₹38,67
Shares outstanding
166,06 m
No. of employees
28 k
News stories
From web sources and news partners
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology. Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe. By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27,5 k
Founded1984
HeadquartersHyderabad, Andhra Pradesh, Indië
SectorPharmaceutical industry
Websitedrreddys.com
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
88,05 mjd
87,27 mjd
75,16 mjd
80,70 mjd
Cost of goods sold
39,91 mjd
40,46 mjd
41,47 mjd
43,16 mjd
Cost of revenue
39,91 mjd
40,46 mjd
41,47 mjd
43,16 mjd
Research and development expenses
6,20 mjd
6,15 mjd
5,46 mjd
5,77 mjd
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26,44 mjd
26,92 mjd
27,76 mjd
28,82 mjd
Operating expense
31,90 mjd
32,48 mjd
32,53 mjd
34,11 mjd
Total operating expenses
71,81 mjd
72,94 mjd
74,00 mjd
77,27 mjd
Operating income
16,24 mjd
14,33 mjd
1,16 mjd
3,43 mjd
Other non operating income
1,28 mjd
570,00 m
512,00 m
-
EBT including unusual items
18,35 mjd
15,43 mjd
1,99 mjd
5,53 mjd
EBT excluding unusual items
17,81 mjd
15,52 mjd
1,82 mjd
4,09 mjd
Income tax expense
4,08 mjd
3,53 mjd
-214,00 m
1,18 mjd
Effective tax rate
22,24%
22,90%
-10,75%
21,32%
Other operating expenses
-740,00 m
-591,00 m
-693,00 m
-477,00 m
Net income
14,37 mjd
12,10 mjd
2,20 mjd
4,44 mjd
Net profit margin
16,32%
13,86%
2,93%
5,50%
Earnings per share
17,87
14,77
5,74
5,33
Interest and investment income
912,00 m
796,00 m
890,00 m
999,00 m
Interest expense
-907,00 m
-944,00 m
-1,06 mjd
-1,26 mjd
Net interest expenses
5,00 m
-148,00 m
-167,00 m
-256,00 m
Depreciation and amortization charges
-
-
-
-
EBITDA
21,29 mjd
19,54 mjd
5,03 mjd
8,80 mjd
Gain or loss from assets sale
-308,00 m
-179,00 m
-2,10 mjd
-368,00 m
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme